Why we do it
We are revolutionizing the drug discovery process for protein therapeutics.
Despite the huge success of protein therapeutics such as insulin, Humira and Herceptin, the overall likelihood of reaching regulatory approval remains low. This is because successfully designing any new protein therapeutic requires the co-optimization of many key properties. Failure to meet the performance requirements on any one of these key properties means the treatments do not make it to market.
Deploying machine learning, alongside automation and synthetic biology, enables us to successfully navigate these complex protein engineering challenges.